Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 17.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,367,551 shares of the biopharmaceutical company’s stock after acquiring an additional 198,624 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in Pfizer were worth $59,242,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Evolution Wealth Advisors LLC acquired a new position in Pfizer in the 2nd quarter worth approximately $34,000. IMA Wealth Inc. raised its holdings in shares of Pfizer by 144.5% during the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 477 shares during the period. Winch Advisory Services LLC raised its holdings in Pfizer by 69.6% in the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 336 shares during the period. Ruggie Capital Group acquired a new position in Pfizer in the 4th quarter valued at about $44,000. Finally, Financial Gravity Wealth Inc. grew its position in Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 257 shares in the last quarter. 71.81% of the stock is owned by institutional investors.
Shares of NYSE PFE traded up $0.25 during trading on Tuesday, hitting $35.64. 595,709 shares of the company traded hands, compared to its average volume of 30,291,382. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27. The firm has a fifty day moving average of $41.55. The firm has a market cap of $202.10 billion, a price-to-earnings ratio of 11.90, a price-to-earnings-growth ratio of 2.90 and a beta of 0.63. Pfizer Inc. has a fifty-two week low of $35.86 and a fifty-two week high of $46.47.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 4.04%. The ex-dividend date of this dividend is Thursday, August 1st. Pfizer’s payout ratio is presently 48.00%.
A number of research analysts recently weighed in on PFE shares. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Morgan Stanley lowered Pfizer from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $48.00 to $40.00 in a research report on Tuesday, July 30th. UBS Group reissued a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. JPMorgan Chase & Co. set a $46.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Monday, July 29th. Finally, Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a report on Monday. Fourteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $46.56.
In other news, insider Alexander R. Mackenzie sold 30,000 shares of the business’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the sale, the insider now directly owns 80,094 shares of the company’s stock, valued at $3,524,136. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Frank A. Damelio sold 153,184 shares of the business’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the sale, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Municipal Bonds
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.